Share this page
Print this page
Email alert
PUBLICATIONS AND PRESENTATIONS
Calistoga Pharmaceuticals' investigational products and therapeutic approach are supported by a number of research and clinical presentations and papers.
- CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 Delta, Demonstrates Clinical Activity and Pharmacodynamic Effects in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. ASH 2010 (View Presentation)
- Phosphoinositide 3-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurselike cells (NLC), in Chronic Lymphocytic Leukemia. ASH 2010 (View Presentation)
- Clinical Safety and Activity in a Phase 1 Study of CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 Delta, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (View Poster)
- A Phase 1 Study of CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3Kinase P110 Delta, in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory B-Cell Malignancies (View Poster)
- CAL-101, a Potent Selective Inhibitor of the P110 Delta Isoform of Phosphatidylinositol 3-Kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals from the Microenvironment in Cellular Models of Hodgkin Lymphoma. (View Poster)
- Clinical Pharmacokinetics of CAL-101, a P110 Delta Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration in Healthy Volunteers and Patients with Hematological Malignancies (View Poster)
- The Role of Phosphatidylinositol 3Kinase-Delta in the Immunomodulatory Effects of Lenalidomide in Chronic Lymphocytic Leukemia (View Poster)
- Evidence of Clinical Activity in a Phase 1 Study of CAL-101, an Oral P110δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies. ASH 12.09 (View Presentation)
- CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment. ASH 2009 (View Presentation)
- Preliminary Evidence of Clinical Activity in a Phase 1 Study of CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. 13th IWCLL Workshop 10.09 (View Presentation)
- Preliminary Evidence of Clinical Activity in a Phase I Study of CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase (P13K), in Patients with Select Hematologic Malignancies. ASCO 2009. (View Abstract)
